AstraZeneca PLC (ZEG)

Overview

AstraZeneca PLC stands as a prominent biopharmaceutical entity, primarily engaged in the discovery, development, manufacture, and commercialization of prescription medications. The company, originally known as Zeneca Group PLC until its rebranding in April 1999, was founded in 1992 and has established its headquarters in Cambridge, United Kingdom. AstraZeneca is renowned for its extensive portfolio of marketed products spanning across various therapeutic areas including cardiovascular, renal, metabolism, oncology, and rare diseases along with a covid-19 vaccine. The company delivers its innovative health solutions globally, serving both primary and specialty care physicians through a network of distributors and local representative offices across the United Kingdom, Europe, the Americas, Asia, Africa, and Australasia. Engaging in strategic collaborations, such as with Neurimmune AG for the development and commercialization of NI006, AstraZeneca continues to reinforce its commitment to addressing unmet medical needs and contributing to the global healthcare landscape.

Products and Services

AstraZeneca's diversified product portfolio addresses a wide range of therapeutic areas, including:

• Cardiovascular, Renal & Metabolism: Products such as Farxiga, Brilinta, and Lokelma are designed to combat various cardiovascular and metabolic conditions, providing essential treatment options for patients worldwide.
• Oncology: The company's oncology portfolio, featuring Tagrisso, Imfinzi, Lynparza, and Calquence, showcases its innovation in cancer treatment, offering hope and improved outcomes for patients facing different types of cancer.
• Respiratory: With products like Symbicort, Fasenra, and Pulmicort, AstraZeneca addresses chronic respiratory diseases, aiming to improve the quality of life for individuals suffering from conditions such as asthma and COPD.
• Immunology: The addition of drugs like Tezspire and Saphnelo highlights the company’s efforts in treating autoimmune diseases and fostering advancements in immunology.
• Covid-19: AstraZeneca has also made significant contributions to the fight against the covid-19 pandemic with its vaccine, Vaxzevria, alongside treatments like Beyfortus, providing critical solutions in these challenging times.
• Rare Diseases: The company’s focus extends to rare diseases with medications like Soliris, Ultomiris, Strensiq, and Kanuma, underscoring its dedication to addressing the needs of patients with less common, yet critical healthcare challenges.

Beyond these products, AstraZeneca is involved in a range of collaborative efforts aimed at enhancing its product offerings and expanding its impact across various dimensions of healthcare and medical treatment.